JP2704214B2 - 非対合システイン残基を有するサイトカイン及びその結合体 - Google Patents

非対合システイン残基を有するサイトカイン及びその結合体

Info

Publication number
JP2704214B2
JP2704214B2 JP5511163A JP51116393A JP2704214B2 JP 2704214 B2 JP2704214 B2 JP 2704214B2 JP 5511163 A JP5511163 A JP 5511163A JP 51116393 A JP51116393 A JP 51116393A JP 2704214 B2 JP2704214 B2 JP 2704214B2
Authority
JP
Japan
Prior art keywords
cytokine
lipophilic
cytokines
cysteine residue
ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP5511163A
Other languages
English (en)
Japanese (ja)
Other versions
JPH07502508A (ja
Inventor
ツェ ウェン チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of JPH07502508A publication Critical patent/JPH07502508A/ja
Application granted granted Critical
Publication of JP2704214B2 publication Critical patent/JP2704214B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP5511163A 1991-12-10 1992-12-10 非対合システイン残基を有するサイトカイン及びその結合体 Expired - Lifetime JP2704214B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80545291A 1991-12-10 1991-12-10
US805,452 1991-12-10
PCT/US1992/010889 WO1993012142A1 (fr) 1991-12-10 1992-12-10 Cytokines dotees d'un residu de cysteine non apparie et leurs produits de conjugaison

Publications (2)

Publication Number Publication Date
JPH07502508A JPH07502508A (ja) 1995-03-16
JP2704214B2 true JP2704214B2 (ja) 1998-01-26

Family

ID=25191607

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5511163A Expired - Lifetime JP2704214B2 (ja) 1991-12-10 1992-12-10 非対合システイン残基を有するサイトカイン及びその結合体

Country Status (5)

Country Link
EP (1) EP0618927A4 (fr)
JP (1) JP2704214B2 (fr)
AU (1) AU666914B2 (fr)
CA (1) CA2124672A1 (fr)
WO (1) WO1993012142A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165458A (en) * 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
WO2000071716A2 (fr) * 1999-05-20 2000-11-30 Scios Inc. Dimeres, facteurs de croissance de l'endothelium vasculaire
CA2373822A1 (fr) 1999-05-20 2000-11-30 Scios Inc. Variants du facteur de croissance endotheliale
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
GB0123262D0 (en) * 2001-09-27 2001-11-21 Adprotech Ltd Polymeric compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533209B1 (fr) * 1982-09-22 1985-11-08 Centre Nat Rech Scient Lipopeptides, leur obtention et leur application comme emulsifiants
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5082967A (en) * 1988-06-16 1992-01-21 Washington University Novel fatty acid analog enzyme substrates
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
WO1991012229A1 (fr) * 1990-02-12 1991-08-22 National Research Council Of Canada Procede de preparation de derives acyles de composes acylables
DK0458064T3 (da) * 1990-05-04 1998-04-27 American Cyanamid Co Stabilisering af somatotropiner ved modificering af cysteinrester

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｃａｎｃｅｒ Ｒｅｓｅｕｒｃｈ，Ｖｏｌ．５１，Ｎｏ．１３，Ｐ．３３６２−３３６６ （１９９１）
Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｉｍｍｕｎｏｌｏｇｙ，Ｖｏｌ．１４７，Ｎｏ．７，Ｐ．２１６４−２１６９ （１９９１）

Also Published As

Publication number Publication date
EP0618927A1 (fr) 1994-10-12
AU666914B2 (en) 1996-02-29
JPH07502508A (ja) 1995-03-16
EP0618927A4 (fr) 1995-05-24
WO1993012142A1 (fr) 1993-06-24
AU3323593A (en) 1993-07-19
CA2124672A1 (fr) 1993-06-24

Similar Documents

Publication Publication Date Title
TWI364295B (en) Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
TWI406672B (zh) 生物效力增進的β干擾素聚合物共軛體
JP3747070B2 (ja) 改良型インターフェロン−ポリマーコンジュゲート
CN100475270C (zh) 一种治疗肿瘤的药物及其应用
US5264209A (en) Modified HIL-6
ES2365000T3 (es) Nuevas composiciones químicamente modificadas de proteína que estimulan eritropoyetina y métodos.
EP1090645B1 (fr) Administration orale de protéines modifiées chimiquement
CN102145178B (zh) Peg化白介素15
ES2255713T3 (es) Factor neurotrofico que se deriva de lineas celulares truncadas gliales.
CN1302209A (zh) 多元醇干扰素β偶联物
EA000415B1 (ru) Стабильные белково-фосфолипидные составы и способы их получения
JP2001518304A (ja) アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用
JP2009501789A (ja) 顆粒球コロニー刺激因子（ｇ−ｃｓｆ）の変異型およびその化学的に抱合されたポリペプチド
JP2704214B2 (ja) 非対合システイン残基を有するサイトカイン及びその結合体
JP2007528347A (ja) 延長された生体内半減期を有するｐｅｇ−生理活性ポリペプチド同種二量体結合体及びその製造方法
KR20100063108A (ko) 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
KR20050083682A (ko) 내인성 에리트로포이에틴의 조직 보호 활성을 유지하는 장기 작용성 에리트로포이에틴
TW201138831A (en) Modified granulocyte colony stimulating factor (G-CSF)
ZA200505393B (en) Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
CN102584979B (zh) PEG化干扰素λ
AU2005335186A1 (en) Human growth hormone conjugated with biocompatible polymer
CN101596320A (zh) 一种治疗肿瘤的药物及其应用
KR100808089B1 (ko) 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
CN101172160A (zh) 干扰素γ偶联物
KR20060132803A (ko) 내인성 에리트로포이에틴의 조직 보호 활성을 유지하는장기 작용성 에리트로포이에틴